Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is the most common adverse event causing drug nonapprovals and drug withdrawals. Using drugs as test agents and measuring a panel of cellular phenotypes that are directly linked to key mechanisms of hepatotoxicity, we have developed an in vitro testing strategy that is predictive of many clinical outcomes of DILI. Mitochondrial damage, oxidative stress, and intracellular glutathione, all measured by high content cellular imaging in primary human hepatocyte cultures, are the three most important features contributing to the hepatotoxicity prediction. When applied to over 300 drugs and chemicals including many that caused rare and idiosyncratic liver toxicity in humans, our testing strategy has a true-positive rate of 50-60% and an exceptionally low false-positive rate of 0-5%. These in vitro predictions can augment the performance of the combined traditional preclinical animal tests by identifying idiosyncratic human hepatotoxicants such as nimesulide, telithromycin, nefazodone, troglitazone, tetracycline, sulindac, zileuton, labetalol, diclofenac, chlorzoxazone, dantrolene, and many others. Our findings provide insight to key DILI mechanisms, and suggest a new approach in hepatotoxicity testing of pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
(2012) · Encyclopedia of the Sciences of Learning · doi:10.1007/978-1-4419-1428-6_5195 · Cited by 19,370
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“The combined preclinical animal testing from rodents, dogs, and monkeys can only identify about half of hepatotoxic drugs in humans (Olson et al., 2000).”
BackgroundLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
The use of receiver operating characteristic curves in biomedical informatics
Lasko, T. A., Bhagwat, J. G., Zou, K. H., & Ohno-Machado, L. (2005) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2005.02.008 · Cited by 823
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735 · cited 1×
“…cultures of human hepatocytes were developed and demonstrated to maintain the differentiated functions of liver metabolism and transport (Bi et al., 2006; Davila et al., 2007; Gross-Steinmeyer et al., 2005; Hewitt et al., 2007; Hoffmaster et al., 2004; LeCluyse et al., 2005; Page et al., 2007).”
BackgroundHepatotoxicity. The adverse effects of drugs and other chemicals on the liver
(1980) · Food and Cosmetics Toxicology · doi:10.1016/0015-6264(80)90206-0 · Cited by 691
O’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0091-3 · Cited by 609 · cited 2×
“…final conclusions from HIAT are distinct from what have been published about these drugs in the past (Chen et al., 2002; Galisteo et al., 2000; Kalgutkar et al., 2005; Laville et al., 2004; O’Brien et al., 2006; Pessayre et al., 1999; Tavintharan et al., 2007; Xu et al., 2003; Zhao et al., 2007).”
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationAdvances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Gerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Drug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
High content screening: seeing is believing
Zanella, F., Lorens, J. B., & Link, W. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.02.005 · Cited by 391
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Deep Learning for Drug-Induced Liver Injury
Xu, Y., Dai, Z., Chen, F., Gao, S., Pei, J., & Lai, L. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00238 · Cited by 382
High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids
Shinozawa, T., Kimura, M., Cai, Y., Saiki, N., Yoneyama, Y., Ouchi, R., Koike, H., Maezawa, M., Zhang, R.-R., Dunn, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.002 · Cited by 378
Ramaiahgari, S. C., den Braver, M. W., Herpers, B., Terpstra, V., Commandeur, J. N. M., van de Water, B., & Price, L. S. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1215-9 · Cited by 364
Unveiling the role of network and systems biology in drug discovery
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.006 · Cited by 346
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“…workers have used multi-parametric analysis in a single cell type (Garside et al. 2014; O’Brien et al. 2006; Persson et al. 2013; Tolosa et al. 2012; Xu et al. 2008) and others a panel of individual cell based and bile-acid transporter inhibition assays (Aleo et al. 2014; Schadt et al. 2015; Shah…”
BackgroundMethodInfluentialEnvironmental Side Effects of Pharmaceutical Cocktails: What We Know and What We Should Know
Vasquez, M. I., Lambrianides, A., Schneider, M., Kümmerer, K., & Fatta-Kassinos, D. (2014) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2014.06.069 · Cited by 295
Wang, J., Hodes, G. E., Zhang, H., Zhang, S., Zhao, W., Golden, S. A., Bi, W., Menard, C., Kana, V., Leboeuf, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02794-5 · Cited by 274
Pluripotent stem cell-derived hepatocyte-like cells
Schwartz, R. E., Fleming, H. E., Khetani, S. R., & Bhatia, S. N. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.003 · Cited by 282
vNN Web Server for ADMET Predictions
Schyman, P., Liu, R., Desai, V., & Wallqvist, A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00889 · Cited by 254
Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
Costa, E. C., de Melo‐Diogo, D., Moreira, A. F., Carvalho, M. P., & Correia, I. J. (2018) · Biotechnology Journal · doi:10.1002/biot.201700417 · Cited by 224
Drug-induced liver injury: a comprehensive review
Hosack, T., Damry, D., & Biswas, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231163410 · Cited by 214
High throughput toxicity screening and intracellular detection of nanomaterials
Collins, A. R., Annangi, B., Rubio, L., Marcos, R., Dorn, M., Merker, C., Estrela‐Lopis, I., Cimpan, M. R., Ibrahim, M., Cimpan, E., et al. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1413 · Cited by 207
“Indeed, a multiparametric assay quantifying oxidative stress, mitochondrial membrane potential and intracellular glutathione levels was capable of accurately predicting hepatotoxicity with a low false positive rate.(68) There is an urgent need to develop HCA assays to evaluate the toxicity of manufactured NMs.”
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
“…suggested, including perturbation of oxidative phosphorylation (Nadanaciva et al., 2007), inhibition of bile export (Horikawa et al., 2003), glutathione depletion (Xu et al., 2008), phospholipidosis due to inhibition of phospholipases (Anderson and Borlak, 2006), and hypersensitivity (Ayd, 1956).”
BackgroundBerger, D. R., Ware, B. R., Davidson, M. D., Allsup, S. R., & Khetani, S. R. (2015) · Hepatology · doi:10.1002/hep.27621 · Cited by 195
Toxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies
Underhill, G. H., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.012 · Cited by 171
Fourches, D., Barnes, J. C., Day, N. C., Bradley, P., Reed, J. Z., & Tropsha, A. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900326k · Cited by 162
Comparative cytotoxicity of nanosilver in human liver HepG2 and colon Caco2 cells in culture
Sahu, S. C., Zheng, J., Graham, L., Chen, L., Ihrie, J., Yourick, J. J., & Sprando, R. L. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.2994 · Cited by 162
“In a similar in vitro study, Xu et al. (2008) used primary human hepatocytes to screen 300 drugs and chemicals that caused liver toxicity in humans to predict their hepatotoxicity in vivo.”
BackgroundInfluentialLauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Li, C. Y., Stevens, K. R., Schwartz, R. E., Alejandro, B. S., Huang, J. H., & Bhatia, S. N. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0667 · Cited by 132
Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent
Li, Y., Couch, L., Higuchi, M., Fang, J.-L., & Guo, L. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs100 · Cited by 120
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“using HepG2 and was later extended by Xu et al.(180) to short-term ECM sandwich cultures of PHHs.”
BackgroundMethodInfluentialGarside, H., Marcoe, K. F., Chesnut-Speelman, J., Foster, A. J., Muthas, D., Gerry Kenna, J., Warrior, U., Bowes, J., & Baumgartner, J. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.10.015 · Cited by 93
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“Spheroidal cultures are not always compatible with high content screening (HCS), in which multiplexed fluorescent readouts are used to screen for DILI liabilities at the organelle level in individual cells (i.e. mitochondria, reactive oxygen species or ROS).”
BackgroundZhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Feng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp033 · Cited by 80
Self-citationRecent advances in AI-based toxicity prediction for drug discovery
Lee, H., Kim, J., Kim, J.-W., & Lee, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1632046 · Cited by 76
Chen, S., Xuan, J., Wan, L., Lin, H., Couch, L., Mei, N., Dobrovolsky, V. N., & Guo, L. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft254 · Cited by 75
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury
Lin, C., & Khetani, S. R. (2016) · BioMed Research International · doi:10.1155/2016/1829148 · Cited by 66
In silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
Mechanisms of tolvaptan-induced toxicity in HepG2 cells
Wu, Y., Beland, F. A., Chen, S., Liu, F., Guo, L., & Fang, J.-L. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.015 · Cited by 41
Development of an AI model for DILI-level prediction using liver organoid brightfield images
Tan, S., Ding, Y., Wang, W., Rao, J., Cheng, F., Zhang, Q., Xu, T., Hu, T., Hu, Q., Ye, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08205-6 · Cited by 26
Ware, B. R., Liu, J. S., Monckton, C. P., Ballinger, K. R., & Khetani, S. R. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab018 · Cited by 25
Liu, J., Li, R., Xue, R., Li, T., Leng, L., Wang, Y., Wang, J., Ma, J., Yan, J., Yan, F., et al. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800110 · Cited by 23
Sasikumar, S., Chameettachal, S., Kingshott, P., Cromer, B., & Pati, F. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00994 · Cited by 18
Drug‐Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools
Dambach, D. M. (2014) · Predictive ADMET · doi:10.1002/9781118783344.ch19 · Cited by 4
Metadata
- Authors
- Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 1
- Pages
- 97-105
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2132272495
- Cited by
- 492
- References
- 61
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.